David Smelson to Schizophrenia
This is a "connection" page, showing publications David Smelson has written about Schizophrenia.
Connection Strength
1.594
-
Smelson DA, Dixon L, Craig T, Remolina S, Batki SL, Niv N, Owen R. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008; 22(11):903-16.
Score: 0.237
-
Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. J Clin Psychopharmacol. 2006 Dec; 26(6):666-7.
Score: 0.219
-
Smelson DA, Ziedonis D, Williams J, Losonczy MF, Williams J, Steinberg ML, Kaune M. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol. 2006 Feb; 26(1):9-12.
Score: 0.207
-
Smelson DA, Davis CW, Eisenstein N, Engelhart C, Williams J, Losonczy MF, Ziedonis D. Cognitive disparity in schizophrenics with and without cocaine dependency. J Subst Abuse Treat. 2003 Jan; 24(1):75-9.
Score: 0.167
-
Smelson DA, Losonczy MF, Kilker C, Starosta A, Kind J, Williams J, Ziedonis D. An analysis of cue reactivity among persons with and without schizophrenia who are addicted to cocaine. Psychiatr Serv. 2002 Dec; 53(12):1612-6.
Score: 0.166
-
Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002 Sep; 47(7):671-5.
Score: 0.163
-
Smelson DA, Davis CW, Di Pano R, Johnson V, Losonczy MF, Ziedonis D. Executive and motor skill functioning among cocaine-dependent schizophrenics and non-drug-abusing schizophrenics. J Nerv Ment Dis. 2002 Mar; 190(3):200-2.
Score: 0.158
-
Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack GW, Grabowski J, Smelson D, Ronis DL, Ganoczy D, Woltmann E, Metreger T, Wolschon P, Jensen A, Poddig B, Blow FC. Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness. Schizophr Bull. 2011 Jul; 37(4):727-36.
Score: 0.067
-
Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005 Sep; 11(5):315-39.
Score: 0.050
-
Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003 Nov 26; 290(20):2693-702.
Score: 0.045
-
Ziedonis D, Williams JM, Smelson D. Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. Am J Med Sci. 2003 Oct; 326(4):223-30.
Score: 0.044
-
Carol G, Smelson DA, Losonczy MF, Ziedonis D. Alcohol & drug abuse: a preliminary investigation of cocaine craving among persons with and without schizophrenia. Psychiatr Serv. 2001 Aug; 52(8):1029-31.
Score: 0.038
-
Howanitz E, Pardo M, Smelson DA, Engelhart C, Eisenstein N, Stern RG, Losonczy MF. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry. 1999 Jan; 60(1):41-4.
Score: 0.032